smart home

Houston home tech startup emerges from stealth with $10M series A round

A Houston startup has launched to keep an eye on your AC to predict and prevent outages and issues. Photo courtesy of SmartAC.com

It can get hot as Hades in Houston during the summer, and a new Houston startup is using machine learning and technology to ensure that users can count on their air conditioning units to stay up and running during the heat.

Houston-based SmartAC.com has emerged from stealth mode with $10 million in funding from a series A investment round. The company's technology focuses on maintaining air conditioning and heating (HVAC) health before a major service issue occurs.

"Over 70 million homes have central air in the U.S., making indoor comfort a regular way of life. People don't often think about their HVAC systems, taking it for granted, until the day the AC or heat goes out," says Josh Teekell, CEO and founder of SmartAC.com, in a news release. "These systems require regular upkeep, and when they aren't maintained, costs can get out of hand. SmartAC.com's offer is simple; we care about your AC so you don't have to."

The company's technology combines three hardware sensors — which users can install themselves — and machine learning software to analyze data to predict service issues. The comfort sensor monitors the temperature of the air coming out of the unit, the filter sensor tracks the lifespan of air filters by tracking pressure and airflow, and the water sensor protects against leaks and clogs.


The three SmartAC.com sensors are magnetic and easy to install. Photo courtesy of SmartAC.com

All three sensors are linked by SmartAC.com Hub, which sends data from the sensors to the cloud and the SmartAC.com app to translate the data into recommendations to help users reduce costs and get ahead of issues.

"The average AC replacement cost is $7,500 — an expense that can be a huge burden on homeowners. Caring for these assets is inconvenient and oftentimes confusing, resulting in 80 percent of homeowners skipping the recommended maintenance on their AC systems," says Andrew Fuselier, SmartAC.com's COO, in a news release. "It's time to digitize the AC ownership experience to solve a decades old problem. SmartAC.com was formed in stealth mode with feedback from thousands of homeowners, so we're thrilled to finally show the world what we've built."

In addition to working directly with consumers, SmartAC.com has teamed up with HVAC service providers.

"SmartAC.com is a total game-changer," says David Lewis of Mission AC in a news release. "Our clients love the additional transparency and the technology allows us to improve our service speed and quality because, for the first time, we have real-time data on the systems we service."

The data from the sensors is analyzed and sent to users via the smart phone app. Photo courtesy of SmartAC.com

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News